前列腺癌立体定向体部放疗与中度大分割放疗后患者报告的生活质量比较
该汇总多中心分析比较了534例接受SBRT(5-10 Gy/次)与378例接受中度大分割放疗(<5 Gy/次)的前列腺癌患者报告的生活质量变化。结果显示,中度大分割组在1年和2年时的肠道和泌尿症状恶化比例均高于SBRT组,性症状无差异;调整年龄和癌症特征后,SBRT组2年泌尿症状恶化的风险更低(OR 0.24,95%CI 0.07-0.79)。
要点
- 性症状评分在两组间1年和2年时无差异。
核心结论
- SBRT与中度大分割放疗后患者报告的肠道和性症状变化相似,但中度大分割组泌尿症状恶化更明显。
研究设计与样本
- 汇总多中心分析,纳入378例接受中度大分割放疗(<5 Gy/次)和534例接受SBRT(5-10 Gy/次)的前列腺癌患者。
主要发现
- 性症状评分在1年和2年时两组间无差异。
- 调整年龄和癌症特征后,SBRT组2年泌尿症状恶化的比值比为0.24(95%CI 0.07-0.79)。
临床怎么用
- 对于临床局限性前列腺癌患者,选择SBRT可能比中度大分割放疗减少泌尿症状恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Evaluate changes in bowel, urinary and sexual patient-reported quality of life following treatment with moderately hypofractionated radiotherapy (<5Gray/fraction) or stereotactic body radiation therapy (SBRT;5-10Gray/fraction) for prostate cancer. MATERIALS AND METHODS: In a pooled multi-institutional analysis of men treated with moderate hypofractionation or SBRT, we compared minimally detectable difference in bowel, urinary and sexual quality of life at 1 and 2years using chi-squared analysis and logistic regression. RESULTS: 378 men received moderate hypofractionation compared to 534 men who received SBRT. After 1year, patients receiving moderate hypofractionation were more likely to experience worsening in bowel symptoms (39.5%) compared to SBRT (32.5%; p=.06), with a larger difference at 2years (37.4% versus 25.3%, p=.002). Similarly, patients receiving moderate fractionation had worsening urinary symptom score compared to patients who underwent SBRT at 1 and 2years (34.7% versus 23.1%, p<.001; and 32.8% versus 14.0%, p<.001). There was no difference in sexual symptom score at 1 or 2years. After adjusting for age and cancer characteristics, patients receiving SBRT were less likely to experience worsening urinary symptom scores at 2years (odds ratio: 0.24[95%CI: 0.07-0.79]). CONCLUSIONS: Patients who received SBRT or moderate hypofractionation have similar patient-reported change in bowel and sexual symptoms, although there was worse change in urinary symptoms for patients receiving moderate hypofractionation.
引用
- Johnson SB, Soulos PR, Shafman TD, et al. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016. PMID: 27890426. doi:10.1016/j.radonc.2016.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。